Following on from information provided to NICE by the company in November 2021, the appraisal of Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 114 |
| Referral date | 01 July 2009 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in November 2021, the appraisal of Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 04 November 2021 | Suspended. For information, the company have announced that they will no longer be pursuing a marketing authorisation application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 6 April 2011 |
The Department of Health has asked us to carry out a single technology appraisal of everolimus within its licensed indication for the prevention of organ rejection in cardiac transplantation. Following on from information received from the manufacturer, dates for this appraisal will be confirmed once regulatory approval timelines are established. |
For further information on our processes and methods, please see our CHTE processes and methods manual